๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond

โœ Scribed by Dumont, Francis J

Book ID
126588563
Publisher
Expert Reviews
Year
2002
Tongue
English
Weight
228 KB
Volume
2
Category
Article
ISSN
1473-7140

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Early treatment of high-risk chronic lym
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab
โœ Clive S. Zent; Timothy G. Call; Tait D. Shanafelt; Renee C. Tschumper; Diane F. ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 162 KB

## Abstract ## BACKGROUND. Patients with chronic lymphocytic leukemia (CLL) usually are treated only for progressive disease. However, the discovery of biologic predictors of a high risk of disease progression, together with the development of newer, more targeted therapies, could change this para